当前位置: X-MOL 学术J. Infect. Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase I Randomized Clinical Trial.
The Journal of Infectious Diseases ( IF 5.0 ) Pub Date : 2020-09-23 , DOI: 10.1093/infdis/jiaa603
Leyi Lin 1 , Michael A Koren 1 , Kristopher M Paolino 2 , Kenneth H Eckels 3 , Rafael De La Barrera 3 , Heather Friberg 1 , Jeffrey R Currier 1 , Gregory D Gromowski 1 , Naomi E Aronson 4 , Paul B Keiser 1 , Marvin J Sklar 5 , Erica L Sondergaard 2 , Louis E Jasper 6 , Timothy P Endy 7 , Richard G Jarman 1 , Stephen J Thomas 1
Affiliation  

Dengue is a global health problem, and the development of a tetravalent dengue vaccine with durable protection is a high priority. A heterologous prime boost strategy has the advantage of eliciting immune responses through different mechanisms and therefore may be superior to homologous prime boost strategies for generating durable tetravalent immunity.

中文翻译:

在 I 期随机临床试验中使用异源 Prime-Boost 策略的减毒活登革热疫苗的免疫原性。

登革热是一个全球性的健康问题,开发具有持久保护作用的四价登革热疫苗是当务之急。异源初免加强策略具有通过不同机制引发免疫反应的优势,因此在产生持久的四价免疫方面可能优于同源初免加强策略。
更新日期:2020-09-28
down
wechat
bug